AACR: AE37 vaccine induces immune response in breast cancer

AACR: AE37 Vaccine Induces Immune Response in Breast CA
AACR: AE37 Vaccine Induces Immune Response in Breast CA

(HealthDay News) -- Patients with breast cancer who are vaccinated with AE37, the Ii-Key hybrid of the human epidermal growth factor receptor 2 (HER2)-derived peptide, together with the immunoadjuvant granulocyte macrophage colony-stimulating factor (GMCSF), have significant immune responses compared with those vaccinated with GMCSF alone, according to a phase II study presented at the annual meeting of the American Association for Cancer Research, held from March 31 to April 4 in Chicago.

Diane F. Hale, M.D., from Brooke Army Medical Center in Fort Sam Houston, Texas, and colleagues randomized disease-free, node-positive or high-risk node negative breast cancer patients with any level of HER2 expression to AE37+GMCSF (vaccine group [VG]; 109 patients) or GMCSF (control group [CG]; 108 patients) intradermal inoculations. Specific immunologic responses were assessed.

The researchers found that the in vitro proliferation responses, measured using the [3H]-thymidine incorporation assay, classified 33.0 percent of VG and 7.4 percent of CG as high responders (P < 0.001); 17.4 and 14.8 percent, respectively, as low responders (P = 0.600); and 49.5 and 77.8 percent, respectively, as non-responders (P < 0.001). Based on in vivo delayed-type hypersensitivity reactions, 86.0 percent of VG and 27.0 percent of CG were classified as responders (P = 0.0001), and 14.0 and 73.0 percent, respectively, were classified as non-responders (P < 0.001). The percentage of patients who had a decrease in their T regulatory cells (Tregs) was significantly higher in the VG group (73.2 versus 54.9 percent; P = 0.048).

"VG patients had significant immunologic responses compared to CG," the authors write. "Monitoring immunologic tests and Tregs throughout the vaccination process may stratify patients into responders and non-responders and thus assist in identifying patients that will have recurrence."

Abstract No. LB-218
More Information

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs